ContraVir Pharmaceuticals to Present at 2017 BIO International Convention
June 13 2017 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today that it will present
at the 2017 Biotechnology Innovation Organization (BIO)
International Convention being held June 19 - 22, 2017 in
San Diego, California.
James Sapirstein, Chief Executive Officer of ContraVir, will
provide an overview of the Company's business during a live
presentation and is available to meet with investors and other
companies who are registered to attend the conference.
Interested parties may contact ContraVir through the BIO
One-on-One Partnering™ system.
Event: |
|
BIO International Conference |
Date: |
|
Wednesday, June 21, 2017 |
Time: |
|
10:45 AM (Pacific Time) |
Location: |
|
Theater 3 |
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the
development and commercialization of targeted antiviral therapies
with a specific focus on developing a potentially curative therapy
for hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™
currently in Phase 2a, is designed to deliver high intrahepatic
concentrations of TFV, while minimizing off-target effects caused
by high levels of circulating TFV. CRV431, the other anti-HBV
compound, is a next-generation cyclophilin inhibitor with a unique
structure that increases its potency and selective index against
HBV. ContraVir is also developing Valnivudine™, an orally available
nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3
for the treatment of herpes zoster. In addition to direct
antiviral activity, Phase 2 data suggest that Valnivudine™ has the
potential to reduce the incidence of debilitating
shingles-associated pain known as post-herpetic neuralgia
(PHN). For more information visit www.contravir.com.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Sep 2023 to Sep 2024